{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:38:54Z","timestamp":1792759134273,"version":"4.5.0"},"reference-count":46,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with schizophrenia spectrum or bipolar disorders have reduced life expectancy due to cardiometabolic risk. We conducted this meta-analysis to evaluate glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for their effects on cardiometabolic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Scopus, Web of Science, and Cochrane up to May 2026 for randomized controlled trials (RCTs). We pooled continuous outcomes as mean differences (MDs) and dichotomous outcomes as risk ratios (RRs) using random-effects models with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      We included 8 RCTs with 664 patients. Compared with control, GLP-1 RA significantly reduced body weight (MD: \u22126.74, 95% CI: \u221210.05 to \u22123.43), body mass index (BMI; MD: \u22122.37\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 95% CI: \u22123.52 to \u22121.23), waist circumference (MD: \u22124.27\u2009cm, 95% CI: \u22126.65 to \u22121.89), HbA1c (MD: \u22120.61%, 95% CI: \u22121.06 to \u22120.17), and fasting glucose (MD: \u22126.82, 95% CI: \u221211.89 to \u22121.76). Subgroup analyses by GLP-1 RA type showed that semaglutide produced the greatest reductions in body weight (MD: \u221211.06\u2009kg) and BMI (MD: \u22123.60\u2009kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ), with significant between-subgroup differences (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Adverse events (AEs;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.77), serious AEs (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.09), and discontinuation due to AEs (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.20) were similar between groups. However, GLP-1 RA was associated with a significantly higher risk of gastrointestinal (GI) AEs, including nausea, vomiting, and constipation (all\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>GLP-1RA, particularly semaglutide, was associated with clinically meaningful improvements in antipsychotic-related cardiometabolic outcomes without compromising psychiatric stability or treatment adherence. However, the significant increase in GI AEs necessitates careful clinical titration. Larger RCTs with longer follow-up are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811261478625","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:32:25Z","timestamp":1789558345000},"page":"1537-1553","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjunctive GLP-1 receptor agonists for cardiometabolic risk in antipsychotic-treated patients: A GRADE-assessed meta-analysis of randomized trials"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6178-8183","authenticated-orcid":false,"given":"Elsayed S.","family":"Moubarak","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Cairo University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-2875","authenticated-orcid":false,"given":"Mohamed S.","family":"Elgendy","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tanta University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Elkoumi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Suez University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Menoufia University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AlMothana","family":"Manasrah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, United Health Services \u2013 Wilson Medical Center, Binghamton, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Ahmad","sequence":"additional","affiliation":[{"name":"College of Medicine and Health Sciences, Palestine Polytechnic University, Hebron, Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak A.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Alexandria University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar ElSayed","family":"Rageh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tanta University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman Aly","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Helwan University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elzahaby","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tanta University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Abuelazm","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Tanta University, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"crossref","unstructured":"Akinola PS Tardif I Leclerc J (2023) Antipsychotic-induced metabolic syndrome: A review. Metabolic Syndrome and Related Disorders 21(6): 294\u2013305. https:\/\/doi.org\/10.1089\/met.2023.0003","DOI":"10.1089\/met.2023.0003"},{"key":"e_1_3_4_3_1","doi-asserted-by":"crossref","unstructured":"Bhat PS Raj J Chatterjee K et al. (2021) Cognitive dysfunction in first-episode schizophrenia and its correlation with negative symptoms and insight. Industrial Psychiatry Journal 30(2): 310\u2013315. https:\/\/doi.org\/10.4103\/ipj.ipj_107_20","DOI":"10.4103\/ipj.ipj_107_20"},{"key":"e_1_3_4_4_1","doi-asserted-by":"crossref","unstructured":"Carli M Kolachalam S Longoni B et al. (2021) Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals 14(3): 238. https:\/\/doi.org\/10.3390\/ph14030238","DOI":"10.3390\/ph14030238"},{"key":"e_1_3_4_5_1","doi-asserted-by":"crossref","unstructured":"Chaudhari B Saldanha D Kadiani A et al. (2017) Evaluation of treatment adherence in outpatients with schizophrenia. Industrial Psychiatry Journal 26(2): 215\u2013222. https:\/\/doi.org\/10.4103\/ipj.ipj_24_17","DOI":"10.4103\/ipj.ipj_24_17"},{"key":"e_1_3_4_6_1","doi-asserted-by":"crossref","unstructured":"Dayabandara M Hanwella R Ratnatunga S et al. (2017) Antipsychotic-associated weight gain: Management strategies and impact on treatment adherence. Neuropsychiatric Disease and Treatment 13: 2231\u20132241. https:\/\/doi.org\/10.2147\/NDT.S113099","DOI":"10.2147\/NDT.S113099"},{"key":"e_1_3_4_7_1","doi-asserted-by":"crossref","unstructured":"Dib T Covarrubias MJ Escobar A et al. (2025) Lateral septum as a key integrative regulator of feeding: Role of the GLP-1\/GLP-1R system. Journal of Neurochemistry 169(11): e70301. https:\/\/doi.org\/10.1111\/jnc.70301","DOI":"10.1111\/jnc.70301"},{"key":"e_1_3_4_8_1","doi-asserted-by":"crossref","unstructured":"Eriksson R Broberg BV Ish\u00f8y PL et al. (2019) Bone status in obese non-diabetic antipsychotic-treated patients and effects of the glucagon-like peptide-1 receptor agonist exenatide on bone turnover markers and bone mineral density. Frontiers in Psychiatry 9: 781. https:\/\/doi.org\/10.3389\/fpsyt.2018.00781","DOI":"10.3389\/fpsyt.2018.00781"},{"key":"e_1_3_4_9_1","doi-asserted-by":"crossref","unstructured":"Filippatos TD Panagiotopoulou TV Elisaf MS (2014) Adverse effects of GLP-1 receptor agonists. The Review of Diabetic Studies 11(3\u20134): 202\u2013230. https:\/\/doi.org\/10.1900\/RDS.2014.11.202","DOI":"10.1900\/RDS.2014.11.202"},{"key":"e_1_3_4_10_1","doi-asserted-by":"crossref","unstructured":"Firth J Siddiqi N Koyanagi A et al. (2019) The lancet psychiatry commission: A blueprint for protecting physical health in people with mental illness. The Lancet Psychiatry 6(8): 675\u2013712. https:\/\/doi.org\/10.1016\/S2215-0366(19)30132-4","DOI":"10.1016\/S2215-0366(19)30387-6"},{"key":"e_1_3_4_11_1","doi-asserted-by":"crossref","unstructured":"Ganeshalingam AA Uhrenholt N Arnfred S et al. (2025) Semaglutide treatment of antipsychotic-treated patients with schizophrenia prediabetes and obesity: The HISTORI randomized clinical trial. JAMA Psychiatry 82(11): 1065\u20131074. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.2332","DOI":"10.1001\/jamapsychiatry.2025.2332"},{"key":"e_1_3_4_12_1","doi-asserted-by":"crossref","unstructured":"Gentile S (2009) Contributing factors to weight gain during long-term treatment with second-generation antipsychotics. A systematic appraisal and clinical implications. Obesity Reviews 10(5): 527\u2013542. https:\/\/doi.org\/10.1111\/j.1467-789X.2009.00589.x","DOI":"10.1111\/j.1467-789X.2009.00589.x"},{"key":"e_1_3_4_13_1","doi-asserted-by":"crossref","unstructured":"Grieco M Giorgi A Gentile MC et al. (2019) Glucagon-like peptide-1: A focus on neurodegenerative diseases. Frontiers in Neuroscience 13: 1112. https:\/\/doi.org\/10.3389\/fnins.2019.01112","DOI":"10.3389\/fnins.2019.01112"},{"key":"e_1_3_4_14_1","doi-asserted-by":"crossref","unstructured":"Guyatt GH Oxman AD Vist GE et al. (2008) GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650): 924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"e_1_3_4_15_1","doi-asserted-by":"crossref","unstructured":"Hamed K Alosaimi MN Ali BA et al. (2024) Glucagon-like peptide-1 (GLP-1) receptor agonists: Exploring their impact on diabetes obesity and cardiovascular health through a comprehensive literature review. Cureus 16(9): e68390. https:\/\/doi.org\/10.7759\/cureus.68390","DOI":"10.7759\/cureus.68390"},{"key":"e_1_3_4_16_1","unstructured":"Higgins JPT Thomas J Chandler J et al. (eds) (2024) Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane. Available at: https:\/\/www.training.cochrane.org\/handbook (accessed 17 July 2026)."},{"key":"e_1_3_4_17_1","doi-asserted-by":"crossref","unstructured":"Huang KP Acosta AA Ghidewon MY et al. (2024) Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature 632(8025): 585\u2013593. https:\/\/doi.org\/10.1038\/s41586-024-07685-6","DOI":"10.1038\/s41586-024-07685-6"},{"key":"e_1_3_4_18_1","doi-asserted-by":"crossref","unstructured":"Ish\u00f8y PL Fagerlund B Broberg BV et al. (2017a) No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated obese patients with schizophrenia. Acta Psychiatrica Scandinavica 136(1): 52\u201362. https:\/\/doi.org\/10.1111\/acps.12711","DOI":"10.1111\/acps.12711"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","unstructured":"Ish\u00f8y PL Knop FK Broberg BV et al. (2017b) Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized placebo-controlled trial. Diabetes Obesity and Metabolism 19(2): 162\u2013171. https:\/\/doi.org\/10.1111\/dom.12795","DOI":"10.1111\/dom.12795"},{"key":"e_1_3_4_20_1","doi-asserted-by":"crossref","unstructured":"Jacobson S Margolese N Margolese HC (2026) GLP-1 receptor agonists as a novel solution for antipsychotic-induced weight gain in severe and persistent mental illness. The Canadian Journal of Psychiatry 71(6): 413\u2013419. https:\/\/doi.org\/10.1177\/07067437251386626","DOI":"10.1177\/07067437251386626"},{"key":"e_1_3_4_21_1","doi-asserted-by":"crossref","unstructured":"Khaity A Mostafa Al-dardery N Albakri K et al. (2023) Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: A systematic review and meta-analysis. Frontiers in Psychiatry 14: 1153648. https:\/\/doi.org\/10.3389\/fpsyt.2023.1153648","DOI":"10.3389\/fpsyt.2023.1153648"},{"key":"e_1_3_4_22_1","doi-asserted-by":"crossref","unstructured":"Larsen JR Vedtofte L Jakobsen MSL et al. (2017) Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: A randomized clinical trial. JAMA Psychiatry 74(7): 719\u2013728. https:\/\/doi.org\/10.1001\/jamapsychiatry.2017.1220","DOI":"10.1001\/jamapsychiatry.2017.1220"},{"key":"e_1_3_4_23_1","doi-asserted-by":"crossref","unstructured":"Leucht S Priller J Davis JM (2024) Antipsychotic drugs: A concise review of history classification indications mechanism efficacy side effects dosing and clinical application. American Journal of Psychiatry 181(10): 865\u2013878. https:\/\/doi.org\/10.1176\/appi.ajp.20240738","DOI":"10.1176\/appi.ajp.20240738"},{"key":"e_1_3_4_24_1","doi-asserted-by":"crossref","unstructured":"Maagensen H Larsen JR J\u00f8rgensen NR et al. (2021) Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes: A randomized controlled trial. Psychiatry Research 296: 113670. https:\/\/doi.org\/10.1016\/j.psychres.2020.113670","DOI":"10.1016\/j.psychres.2020.113670"},{"key":"e_1_3_4_25_1","doi-asserted-by":"crossref","unstructured":"Mansour MEM Alsaadany KR Mustafa MMM et al. (2026) Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 55 clinical trials. Journal of Psychopharmacology 40(4): 621\u2013631. https:\/\/doi.org\/10.1177\/02698811251399544","DOI":"10.1177\/02698811251399544"},{"key":"e_1_3_4_26_1","doi-asserted-by":"crossref","unstructured":"Mitchell AJ Vancampfort D Sweers K et al. (2013) Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders: A systematic review and meta-analysis. Schizophrenia Bulletin 39(2): 306\u2013318. https:\/\/doi.org\/10.1093\/schbul\/sbr148","DOI":"10.1093\/schbul\/sbr148"},{"key":"e_1_3_4_27_1","doi-asserted-by":"crossref","unstructured":"Nutt DJ Blier P (2016) Neuroscience-based Nomenclature (NbN) for Journal of Psychopharmacology. Journal of Psychopharmacology 30(5): 413\u2013415. https:\/\/doi.org\/10.1177\/0269881116642903","DOI":"10.1177\/0269881116642903"},{"key":"e_1_3_4_28_1","doi-asserted-by":"crossref","unstructured":"Page MJ McKenzie JE Bossuyt PM et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 372: n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_29_1","doi-asserted-by":"crossref","unstructured":"Park JS Kim KS Choi HJ (2025) Glucagon-like peptide-1 and hypothalamic regulation of satiation: Cognitive and neural insights from human and animal studies. Diabetes & Metabolism Journal 49(3): 333\u2013347. https:\/\/doi.org\/10.4093\/dmj.2025.0106","DOI":"10.4093\/dmj.2025.0106"},{"key":"e_1_3_4_30_1","doi-asserted-by":"crossref","unstructured":"Patino LR Strawn JR Adler CM et al. (2025) A double-blind placebo-controlled trial of exenatide for the treatment of olanzapine-related weight gain in obese and overweight adults. Journal of Affective Disorders 382: 116\u2013122. https:\/\/doi.org\/10.1016\/j.jad.2025.04.046","DOI":"10.1016\/j.jad.2025.04.046"},{"key":"e_1_3_4_31_1","doi-asserted-by":"crossref","unstructured":"Penninx BWJH Lange SMM (2018) Metabolic syndrome in psychiatric patients: Overview mechanisms and implications. Dialogues in Clinical Neuroscience 20(1): 63\u201373. https:\/\/doi.org\/10.31887\/DCNS.2018.20.1\/bpenninx","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx"},{"key":"e_1_3_4_32_1","doi-asserted-by":"crossref","unstructured":"Rena G Hardie DG Pearson ER (2017) The mechanisms of action of metformin. Diabetologia 60(9): 1577\u20131585. https:\/\/doi.org\/10.1007\/s00125-017-4342-z","DOI":"10.1007\/s00125-017-4342-z"},{"key":"e_1_3_4_33_1","doi-asserted-by":"crossref","unstructured":"Reynolds GP Hill MJ Kirk SL (2006) The 5-HT2C receptor and antipsychotic-induced weight gain: Mechanisms and genetics. Journal of Psychopharmacology 20(4_suppl): 15\u201318. https:\/\/doi.org\/10.1177\/1359786806066040","DOI":"10.1177\/1359786806066040"},{"key":"e_1_3_4_34_1","doi-asserted-by":"crossref","unstructured":"Ringen PA Engh JA Birkenaes AB et al. (2014) Increased mortality in schizophrenia due to cardiovascular disease: A non-systematic review of epidemiology possible causes and interventions. Frontiers in Psychiatry 5: 137. https:\/\/doi.org\/10.3389\/fpsyt.2014.00137","DOI":"10.3389\/fpsyt.2014.00137"},{"key":"e_1_3_4_35_1","doi-asserted-by":"crossref","unstructured":"Sass MR Klausen MK Schwarz CR et al. (2026) Semaglutide and early-stage metabolic abnormalities in individuals with schizophrenia spectrum disorders: A randomized clinical trial. JAMA Psychiatry 83(2): 128\u2013138. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.3639","DOI":"10.1001\/jamapsychiatry.2025.3639"},{"key":"e_1_3_4_36_1","doi-asserted-by":"crossref","unstructured":"Seiter HT Fellendorf FT Popkova D et al. (2025) Weight gain under antipsychotic and mood stabilizing treatment: A narrative review about mechanisms and future options. International Journal of Bipolar Disorders 13(1): 33. https:\/\/doi.org\/10.1186\/s40345-025-00397-4","DOI":"10.1186\/s40345-025-00397-4"},{"key":"e_1_3_4_37_1","doi-asserted-by":"crossref","unstructured":"Singh R Bansal Y Medhi B et al. (2019) Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights therapeutic targets and pharmacological alternatives. European Journal of Pharmacology 844: 231\u2013240. https:\/\/doi.org\/10.1016\/j.ejphar.2018.12.003","DOI":"10.1016\/j.ejphar.2018.12.003"},{"key":"e_1_3_4_38_1","doi-asserted-by":"crossref","unstructured":"Siskind DJ Baker A Arnautovska U et al. (2025) Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): A phase 2 multi-centre participant- and investigator-blinded randomised controlled trial in Australia. The Lancet Psychiatry 12(7): 493\u2013503. https:\/\/doi.org\/10.1016\/S2215-0366(25)00129-4","DOI":"10.1016\/S2215-0366(25)00129-4"},{"key":"e_1_3_4_39_1","doi-asserted-by":"crossref","unstructured":"Siskind DJ Russell AW Gamble C et al. (2018) Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX). Diabetes Obesity and Metabolism 20(4): 1050\u20131055. https:\/\/doi.org\/10.1111\/dom.13167","DOI":"10.1111\/dom.13167"},{"key":"e_1_3_4_40_1","doi-asserted-by":"crossref","unstructured":"Skibicka KP (2013) The central GLP-1: Implications for food and drug reward. Frontiers in Neuroscience 7: 181. https:\/\/doi.org\/10.3389\/fnins.2013.00181","DOI":"10.3389\/fnins.2013.00181"},{"key":"e_1_3_4_41_1","doi-asserted-by":"crossref","unstructured":"Sood M Ganesh R Mahapatra A et al. (2023) Somatic symptoms in schizophrenia: Association with socio-demographic and clinical characteristics disability and quality of life. Indian Journal of Psychiatry 65(7): 749\u2013754. https:\/\/doi.org\/10.4103\/indianjpsychiatry.indianjpsychiatry_571_22","DOI":"10.4103\/indianjpsychiatry.indianjpsychiatry_571_22"},{"key":"e_1_3_4_42_1","doi-asserted-by":"crossref","unstructured":"Sterne JAC Savovi\u0107 J Page MJ et al. (2019) RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 366: l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_3_4_43_1","doi-asserted-by":"crossref","unstructured":"Svensson CK Larsen JR Vedtofte L et al. (2019) One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatrica Scandinavica 139(1): 26\u201336. https:\/\/doi.org\/10.1111\/acps.12982","DOI":"10.1111\/acps.12982"},{"key":"e_1_3_4_44_1","unstructured":"Swarup S Ahmed I Grigorova Y et al. (2025) Metabolic syndrome. StatPearls. StatPearls Publishing. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459248\/ (accessed 17 July 2026)."},{"key":"e_1_3_4_45_1","doi-asserted-by":"crossref","unstructured":"Wetterslev J Jakobsen JC Gluud C (2017) Trial sequential analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology 17(1): 39. https:\/\/doi.org\/10.1186\/s12874-017-0315-7","DOI":"10.1186\/s12874-017-0315-7"},{"key":"e_1_3_4_46_1","doi-asserted-by":"crossref","unstructured":"Whicher CA Price HC Phiri P et al. (2021) The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia schizoaffective disorder and first episode psychosis: Results of a pilot randomized double-blind placebo-controlled trial. Diabetes Obesity and Metabolism 23(6): 1262\u20131271. https:\/\/doi.org\/10.1111\/dom.14334","DOI":"10.1111\/dom.14334"},{"key":"e_1_3_4_47_1","doi-asserted-by":"crossref","unstructured":"Zhang JP Gallego JA Robinson DG et al. (2013) Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology 16(6): 1205\u20131218. https:\/\/doi.org\/10.1017\/S1461145712001277","DOI":"10.1017\/S1461145712001277"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261478625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811261478625","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811261478625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:51:16Z","timestamp":1792756276000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811261478625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/02698811261478625"],"URL":"https:\/\/doi.org\/10.1177\/02698811261478625","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}